Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pep2Dia is a patented milk protein hydrolysate containing an active dipeptide called Alanine-Proline (AP), specifically designed to help manage blood sugar levels. Based on the search results, I can provide the following comprehensive information about this ingredient: ## Product Overview Pep2Dia is developed by Ingredia, a French company specializing in dairy ingredients. It's the first patented dairy hydrolysate specifically designed for prediabetes management and blood sugar regulation. The active component in Pep2Dia is the AP dipeptide (Alanine-Proline), which works by inhibiting alpha-glucosidase, an intestinal enzyme responsible for converting complex sugars into glucose[3][4]. ## Mechanism of Action The primary mechanism of Pep2Dia is alpha-glucosidase inhibition. By inhibiting this digestive enzyme, Pep2Dia reduces the conversion of complex carbohydrates into simple sugars, thereby lowering blood glucose levels after meals (postprandial glycemia)[3][5]. Clinical studies have demonstrated that Pep2Dia can reduce postprandial glycemia by approximately 21% following a high-sugar meal[3]. Additionally, research has shown that Pep2Dia treatment increases GLP-1 plasma levels and may inhibit lipogenesis by decreasing FAS and SREBP-1c gene expressions in adipose tissue[2]. ## Safety and Efficacy Pep2Dia has undergone extensive preclinical and clinical testing to demonstrate both its efficacy and safety. These studies were conducted according to OCDE guidelines and clinical gold standards, including randomization, double-blind protocols, and placebo controls[1]. The ingredient has been shown to be free of side effects and toxicity when used at the recommended dosage of 1.4g taken 15 minutes before a meal[1]. In the United States, Pep2Dia has received GRAS (Generally Recognized As Safe) status[1] and has also received FDA approval for its New Dietary Ingredient Notification (NDIN)[7]. As of April 2022, Pep2Dia has received two structure-function claims in the US: - "Helps to maintain healthy blood sugar levels after meals" - "Helps to support healthy blood sugar levels"[8] ## Production and Quality Pep2Dia is a 100% natural product derived from cow's milk sourced from an integrated dairy chain in northern France, around the town of Arras[3]. Ingredia applies Good Manufacturing Practices and Quality Procedures in accordance with European legislation and has earned several quality certifications including ISO 9001, ISO 50001, and FSSC 22000[1]. The production process involves gentle milk separation methods and hydrolysis of milk protein to create the bioactive ingredient containing the AP dipeptide[3]. ## Target Population Pep2Dia is specifically designed for individuals with prediabetes to help manage blood sugar levels and potentially delay or prevent the progression to type 2 diabetes[2][5]. Research suggests it could be beneficial for subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pep2Dia.